Disease name and synonyms
=========================

Frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17).

Definition/diagnostic criteria
==============================

The term frontotemporal dementia and parkinsonism linked to chromosome 17 was defined during the International Consensus Conference in Ann Arbor, Michigan, in 1996 \[[@B1]\]. At the time, affected individuals with frontotemporal dementia and parkinsonism linked to the *wld*locus on chromosome 17 had been identified within 13 families. This syndrome is a familial disorder with autosomal dominant inheritance. The three major clinical features include behavioral disturbances, cognitive impairment, and parkinsonism. There are no strict diagnostic criteria for FTDP-17. Nevertheless, FTDP-17 should be considered in the differential diagnosis in the presence of one or more of the following \[[@B2]\]:

• Age of onset of neurological symptoms between the third and fifth decades;

• Progressive neuropsychiatric syndrome including personality and behavioral abnormalities and/or frontotemporal dementia;

• Parkinsonism-plus syndrome (bradykinesia, rigidity, postural instability, paucity of resting tremor, and poor or no response to dopaminergic therapy) frequently associated with falls and supranuclear gaze palsy and less commonly associated with apraxia, dystonia, and lateralization;

• Progressive speech difficulties from the onset of the illness;

• Seizure disorder poorly controlled by standard anticonvulsant therapy;

• Positive family history suggestive of autosomal dominant inheritance of a neurodegenerative disorder, even if there has been variability in clinical presentations.

Epidemiology
============

FTDP-17 is an extremely rare condition. Its prevalence and incidence remain unknown. Over 100 families with FTDP-17 have been reported to date in numerous countries (USA, Great Britain, Japan, Netherlands, France, Canada, Australia, Italy, Germany, Israel, Ireland, Spain and Sweden). Some of these families share a common founder \[[@B3]\]. We estimate that there have been about 50--600 patients described, with fewer than 70 individuals still living. Molecular genetic studies have identified 38 unique mutations in these families (Figure [1](#F1){ref-type="fig"}). The most common mutations, accounting for approximately 60% of known cases, are P301L, N279K and a splice site mutation (exon 10 +16) \[[@B4]\].

![Schematic representation of the exons and introns of the tau gene localized on chromosome 17. The 38 mutations identified so far are presented.](1750-1172-1-30-1){#F1}

Etiology
========

Mutations in the *tau*gene account for the vast majority of FTDP-17 cases. Tau is a microtubule-binding protein abundant in neurons and glia. In neurons, it is predominantly expressed in axons. Tau binds to and stabilizes microtubules and promotes microtubule assembly. The majority of the currently known mutations in coding region occur within the microtubule-binding region of *tau*gene. Most known mutations in non-coding regions affect the splicing of exon 10 \[[@B4]\]. The pathogenetic mechanisms in FTDP-17 are thought to be related to the altered proportion of tau isoforms or to the ability of tau to bind microtubules and to promote microtubule assembly.

Mutations in *tau*gene associated with FTDP-17 fall into two broad mechanistic groups. One group contains coding mutations (missense and two deletions) that, in recombinant protein studies and in transfected cell assays, have been shown to disrupt the binding of tau to microtubules. In addition, the majority of these mutations have also been shown to accelerate the aggregation of recombinant tau in the presence of polyanions. Thus, overall, these mutations are predicted both to increase the proportion of tau that is unbound to microtubules and available for aggregation and also to increase directly the tendency of the unbound tau to form filaments. The second group of *tau*mutations appears to cause disease by disrupting the alternative splicing of exon 10 and hence the ratio of 4R: 3R *tau*. These mutations comprise a mixture of coding changes, within exon 10 (N279K, delK280, L284L, N296N/H, delN296, P301L/S, G303V, and S305S/N) and also intronic mutations close to the 5\' splice site of exon 10 (at positions +3, +11, +12, +13, +14, +16, +19, and +29). All but three of these mutations have been demonstrated to increase the splicing-in of exon 10 and hence the proportion of 4R *tau*. The exceptions are delK280, +19, and, +29 mutations that show increased 3R: 4R ratio as compared with normal condition \[[@B5]\]. The +29 mutation has been detected in both affected individuals with the FTD phenotype and normal controls \[[@B6]-[@B8]\]. Therefore, it is still unclear whether this splicing mutation contributes to disease development.

Families with FTD linked to chromosome 17q21 without tau mutations
------------------------------------------------------------------

Six FTDP-17 kindreds have been identified in which neither a *tau*mutation nor tau pathology has been detected, despite genetic linkage to the same region of chromosome 17q21 that contains the *tau*gene \[[@B7]-[@B12]\]. Their clinical phenotype is indistinguishable from that of cases with known *tau*mutations. The specific mutations and their clinical presentations are summarized in Table [1](#T1){ref-type="table"}. Studies of this group of individuals provide valuable information for elucidating the etiology of FTDP-17, as it introduces the possibility that further mutations in the introns or regulatory regions of *tau*, or other causative genes near the *tau*locus may yet be discovered. For example, mutations in the intronic sequence adjacent to the stem loop structure in exon 10 have been identified that alter *tau*splicing to increase soluble 3R *tau*, leading to increased tau proteolysis and neuronal apoptosis without deposition of insoluble tau aggregates \[[@B13]\].

###### 

Families with FTD linked to chromosome 17q21 without *tau*mutations.

  Author                                                Froelich *et al*. \[7\]                                            Rosso *et al*. \[8\]                                                                                Lendon *et al*. \[9\]\*                                                                            Rademakers *et al*. \[10\]                                   Kertesz *et al*. \[11\]            Bird *et al*. \[12\]^†^
  ----------------------------------------------------- ------------------------------------------------------------------ --------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------- ------------------------------------------------------------ ---------------------------------- -----------------------------------------------------
  Pedigree                                                                                                                                                                                                                                                                                                                                                                                                                        
  Origin                                                Sweden                                                             Germany                                                                                             USA                                                                                                Netherlands                                                  Canada                             USA
  No. of FA/G/AI                                        20/4/11                                                            NA/4/32                                                                                             \>10,000/8/24                                                                                      73/4/16                                                      30/4/10                            52/4/18
  Mean ± SD age at onset, y                             51 ± 3.6                                                           61.2 ± 8.8                                                                                          60.4 ± 0.5                                                                                         64.9 ± 8.9                                                   63.4 ± 12.5                        54.7 ± 7.5
  Mean ± SD disease duration, y                         2.9 ± 0.8                                                          8.6 ± 2.9                                                                                           6.9 ± 2.2                                                                                          6.6 ± 2.6                                                    4.0 ± 2.7                          10.1 ± 5.2
  Clinical characteristics                                                                                                                                                                                                                                                                                                                                                                                                        
   Initial sign                                         D                                                                  D/PC                                                                                                D                                                                                                  D/PC                                                         PC                                 PC (PS)
   Dementia                                             \+                                                                 \+                                                                                                  \+                                                                                                 \+                                                           \+                                 \+
   Other features                                       Apraxia, dysphagia                                                 LD                                                                                                  LD, EP, hemiparesis                                                                                LD                                                           LD, dysphagia                      Myoclonus
  Predominant clinical phenotype                        FTD                                                                FTD                                                                                                 FTD (HDD)                                                                                          FTD                                                          FTD (Pick complex)                 FTD
  Pathologic findings                                   Severe frontal lobe degeneration with spongy changes and gliosis   Severe frontal lobe degeneration with neuronal loss and gliosis Neuronal loss in the hippo-campus   Severe frontal lobe degeneration with neuronal loss and gliosis Neuronal loss in the hippocampus   Frontotemporal degeneration with neuronal loss and gliosis   Frontotemporal lobe degeneration   Tau-positive NFT in the neocortex and limbic system
  Ubiquitin-positive neuronal intranuclear inclusions   \+                                                                 \+                                                                                                  NR                                                                                                 \+                                                           \+                                 NR
  Max lod score for chromosome 17q21                    2.68                                                               3.46                                                                                                3.68                                                                                               5.51                                                         1.68                               1.11

+, present; AI, affected individual; D, dementia; EP, extrapyramidal signs; FA, family member; FTD, frontotemporal dementia; G, generation; HDD, hereditary dysphasic dementia; LD, language difficulties; NA, not available; NFT, neurofibrillary tangles; NR, not reported; PC, personality change; PS, psychiatric symptom.

\*Data are from individuals with some form of dementia in recent generations of the family

Extensive ubiquitin-positive, tau-negative, cytoplasmic and intranuclear neuronal inclusions have been observed in layer II of the cerebral cortex and in the dentate gyrus of the hippocampus in three of the kindreds lacking a *tau*mutation \[[@B14],[@B15]\]. The intranuclear inclusions are unlikely to result from a trinucleotide repeat expansion mutation in that they failed to stain when exposed to an antibody that recognizes proteins with polyglutamine tracts \[[@B7]\]. Descriptions of similar intranuclear inclusions in patients with FTD and motor neuron disease \[[@B14],[@B15]\] suggest that they may turn out to be specific for chromosome 17-linked FTD without *tau*mutations.

Clinical description
====================

Symptoms and signs
------------------

The onset of FTDP-17 is usually insidious. Affected individuals who have reached the fully developed stage of the disease present with a constellation of signs including at least two of the three cardinal features of FTDP-17.

• Behavioral and personality disturbances;

• Cognitive deficits;

• Motor dysfunction (typically signs of parkinsonism-plus syndrome).

Clinical features of FTDP-17 vary considerably among affected individuals, regardless of whether they inherit the same or different mutations. Even members within a family, for example, can vary in their clinical presentation. The specific mutations and their characteristic clinical presentations are summarized in Table [2](#T2){ref-type="table"}.

###### 

Phenotypes of specific *tau*gene mutations seen in FTDP-17 patients.

  --------------------------------------------------------------------------------------------------------
                            Exon                                                                     
  ------------------------- ------ ------------- ------- ------------- ------- --------- ----- ----- -----
  Average age at onset, y                                                                            

   ≤30                                                   S352L                 P301S                 

                                                         G335V                                       

   31--40                          L266V         S320F                 G389R   delN296               

                                                                               S305N                 

                                                                               G303V                 

   41--50                          G272V         K317M   E342V                 N279K     +3    +11   +14

                                   K257T                                       P301L     +16         

   \>50                     R5H    I260V         L315R   V337M         R406W   del280K   +12   +13   +19

                            R5L                          Q336R         T427M   L284L     +29         

                                                         K369I                 N296H                 

                                                                               S305S                 

                                                                               N296N                 

  Average duration, y                                                                                

   ≤5                       R5H    L266V         L315R   S352L         G389R   del280K   +29         

                            R5L    K257T                                       delN296               

                                                                               N296H                 

                                                                               S305N                 

                                                                               G303V                 

   6--10                           G272V I260V   K317M   E342V Q336R   T427M   N279K\    +11   +12   
                                                                               P301L                 

                                                         K369I                 S305S                 

                                                         G335V                 N296N                 

                                                                               L284L                 

                                                                               P301S                 

   11--15                                        S320F   V337M                           +3    +14   +16

   \>15                                                                R406W                         

  First sign                                                                                         

   Parkinsonism             R5L                  K317M                         N279K     +3    +11   

                                                                               P301L                 

                                                                               delN296               

                                                                               S305S                 

                                                                               N296N                 

                                                                               G303V                 

   Dementia                 R5H    K257T         S320F   Q336R         R406W   L284L     +3    +12   +29

                                                 L315R                         delN296               

   Personality change              G272V         L315R   V337M         T427M   P301L     +12   +14   +16

                                   I260V                 E342V                 N296H     +19   +29   

                                                         K369I                 S305S                 

                                                         G335V                 S305N                 

  Parkinsonism                                                                                       

   Early-prominent                               K317M                         N279K     +11         

                                                                               delN296               

                                                                               S305S                 

                                                                               N296N                 

                                                                               G303V                 

   Late-prominent                                                              P301S     +3    +12   +14

                                                                               N296H     +16   +29   

   Rare-minimal             R5L    G272V                 S352L                 P301L                 

                                                                               S305N                 

  Dementia                                                                                           

   Early-prominent                 L266V         S320F   Q336R         R406W   delN296   +12   +29   

                                   K257T         L315R   G335V         T427M   S305S                 

                                   I260V                                                             

   Late-prominent                  G272V                 V337M                 del280K   +3    +11   +13

                                                         K369I                 L284L                 

                                                                               P301L                 

                                                                               P301S                 

                                                                               S305N                 

   Rare-minimal                                  K317M                         N279K\                
                                                                               G303V                 

  Personality change                                                                                 

   Early-prominent                 L266V         L315R   V337M         R406W   del280K   +12   +14   +16

                                   G272V                 K369I         T427M   L284L     +19   +29   

                                   I260V                 G335V                 P301L                 

                                   K257T                                       P301S                 

                                                                               S305S                 

                                                                               S305N                 

  Other clinical features                                                                            

   Language s                      G272V         S320F   Q336R         G389R   N279K     +14   +16   +29

   difficultie                     K257T         L315R                 T427M   L284L                 

                                   I260V         K317M                         N296H                 

                                                                               P301L                 

                                                                               S305S                 

                                                                               N296N                 

                                                                               G303V                 

   Late mutism                                   L315R   V337M         R406W   N279K     +16   +29   

                                                                       T427M   del280K               

                                                                               N296H                 

                                                                               P301S                 

                                                                               S305N                 

   Eye movement                                                                N279K     +3          

   abnormalities                                                               N296H                 

                                                                               P301S                 

                                                                               delN296               

                                                                               S305S                 

                                                                               N296N                 

                                                                               G303V                 

   Epilepsy                                              S352L                 P301S                 

   Myoclonus                                             V337M                 N279K     +11         

                                                         S352L                 P301S                 

   Pyramidal signs                                                             N279K     +3    +12   

                                                                               P301S                 

                                                                               N296N                 

                                                                               G303V                 

                                                                               S305S                 

   Amyotrophy                                    K317M                         P301L\    +14         
                                                                               N296N                 
  --------------------------------------------------------------------------------------------------------

The behavioral and personality abnormalities can include disinhibition, apathy, defective judgment, compulsive behavior, hyper-religiosity, neglect of personal hygiene, alcoholism, illicit drug addiction, verbal and physical aggressiveness, family abuse, and other manifestations. While cognitive disturbances occur, memory, orientation, and visuospatial function are relatively preserved during early stages of the disease. Progressive speech difficulties with non-fluent aphasia and disorders of executive functions can be seen initially. Subsequently, memory, orientation, and visuospatial functions progressively deteriorate, while echolalia, palilalia, verbal and vocal perseverations develop. Finally, progressive dementia and mutism occur. Motor signs are also prominent. Parkinsonism can be the first manifestation of the disease, and in this regard it is important to note that some FTDP-17 patients were initially misdiagnosed as having Parkinson\'s disease or sporadic progressive supranuclear palsy. In some families, however, the parkinsonism occurs late in the course of the illness or not at all. The parkinsonism in FTDP-17 is characterized by rather symmetrical bradykinesia, postural instability, rigidity affecting equally axial and appendicular musculature, (usually) absence of resting tremor, and poor or no responsiveness to levodopa therapy. Other motor disturbances seen in FTDP-17 include dystonia unrelated to medications, supranuclear gaze palsy, upper and lower motor neuron dysfunction, myoclonus, postural and action tremors, eyelid opening and closing apraxia, dysphagia, and dysarthria.

Phenotype-genotype correlations
-------------------------------

It is still very difficult to perform precise phenotype/genotype correlations in FTDP-17 since the clinical information available for some families is not detailed enough in or not accessible at all. Nevertheless, some patterns have emerged. The families with FTDP-17 fall into two major groups \[[@B16]\]:

• dementia predominant phenotype;

• parkinsonism-plus predominant phenotype.

The dementia predominant phenotype is more common and is usually seen in families with mutations in exons 1, 9, 11, 12, 13 and in exon 10.

The parkinsonism-plus predominant phenotype is usually seen in families with intronic and exonic mutations affecting exon 10 and leading to the selective overproduction of 4R *tau*isoforms. These categorizations should be viewed cautiously until more clinical and pathologic data become available.

Diagnostic methods
==================

Characteristic clinical and pathological features of FTDP-17 coupled with a molecular genetic analysis of the *tau*gene are essential steps for a diagnosis.

Imaging studies such as computerized tomography (CT) and magnetic resonance imaging (MRI) can assist in establishing a diagnosis, mainly by excluding other diagnostic possibilities such as the presence of a brain tumor, abscess, multi-infarct state, or hydrocephalus.

Imaging studies
---------------

CT and MRI of the head usually demonstrate some dilation of the ventricular system and frontal, temporal, and parietal cortical atrophy (Figure [2A](#F2){ref-type="fig"}) \[[@B17]-[@B22]\]. MRI T2-weighted images may show accumulation of paramagnetic substances (iron) in mesencephalic nuclei \[[@B19]\]. In some kindreds, asymmetrical cortical atrophy is present. Functional imaging studies such as single photon emission computerized tomography (SPECT) and positron emission tomography (PET) also demonstrate significant abnormalities. PET with 2-deoxy-2-fluoro- \[^18^F\]-D-glucose (FDG) usually shows reduced frontal-parietal-temporal uptake patterns similar to those seen in sporadic frontotemporal dementia (FTD). PET with \[^18^F\]-fluoro-L-dopa (6FD) and \[^11^C\]-raclopride tracers reveals uptake abnormalities distinct from those seen in PD, in which the putamen is affected more than the caudate nucleus \[[@B23]\].

![A) Head MRI (left panels) demonstrates cortical atrophy in frontal and temporal lobes. Positron emission tomography (PET) with 2-deoxy-2-fluoro- \[^18^F\]-D-glucose (FDG) PET (right panels) demonstrates hypometabolism in the same cortical regions. Middle panels show co-registration of MRI and FDG PET studies. B) Thermoregulatory sweating tests in the same patient with PPND. Shaded areas represent sweating over the anterior body surface. Distal anhidrosis is seen.](1750-1172-1-30-2){#F2}

Laboratory findings
-------------------

The routine serum, urine, cerebrospinal fluid and other body fluid studies are usually negative. Electroencephalography (EEG) findings are normal early in the disease process and progress to diffuse slowing as the disease advances, although slowing can sometimes be seen earlier in the course of the FTDP-17 illness \[[@B24]\]. In sporadic FTD, the slowing of background rhythms usually occurs late in the course of the illness. In individuals with the P301S mutation, EEG demonstrates sharp waves, spikes and epileptiform discharges \[[@B25]\]. Nerve conduction studies are normal. Electromyography may show neurogenic patterns related to lower motor neuron dysfunction \[[@B26]\]. Evoked potential studies are usually normal. Autonomic testing may show sudomotor impairment but not orthostatic hypotension (Figure [2B](#F2){ref-type="fig"}) \[[@B27]\]. There is very little information available on sleep studies in FTDP-17 kindreds. In a clinicopathological study of an affected patient with G389R mutation, a relationship between the reduced delta sleep and the decreased cortical and subcortical connectivity was reported \[[@B28]\]. Neuropsychological evaluation is of paramount significance in determining the severity and extent of cognitive and behavioral dysfunction in this disorder.

Differential diagnosis
======================

Clinically, FTDP-17 may mimic several neurodegenerative diseases. The differential diagnosis of FTDP-17 includes disorders with initial signs such as behavioral and personality abnormalities, parkinsonism, lower motor neuron dysfunction or cognitive impairments. In the absence of a positive family history or molecular genetic data, FTDP-17 is most frequently confused with Pick\'s disease, sporadic progressive supranuclear palsy (PSP) or corticobasal degeneration (CBD). Other familial frontotemporal dementias, parkinson-plus syndromes, dementia with Lewy bodies (DLB), Parkinson\'s disease (PD), multiple system atrophy (MSA) should be excluded. A neuropathologic examination coupled with molecular genetic analysis of the *tau*gene are essential steps towards distinguishing FTDP-17 from other neurodegenerative diseases associated with tau deposition. The pathologic analysis should include immunohistochemical studies using multiple anti-tau antibodies.

Genetic counseling
==================

Affected individuals should be counseled regarding the estimated probability of passing the genetic bases for their illness on to their offspring. As FTDP-17 is an autosomal dominantly inherited condition, each offspring of an affected individual will carry a 50% risk of inheriting the abnormal gene. Some of these mutations can be detected through genetic testing. The individual who inherits a mutation will not necessarily develop the same clinical syndrome as the parent, because penetrance may be incomplete, neurologic manifestations vary greatly even within families, or the individual might die from unrelated causes. In the case of the pallido-ponto-nigral degeneration (PPND) subtype of FTDP-17, however, penetrance is complete and virtually all individuals who inherit the mutation will become symptomatic during middle age.

At-risk individuals may sometimes choose to adopt rather than bear their own children. When faced with the option of genetic testing, some people prefer the greater certainty that a genetic diagnosis may afford when planning life decisions, while others find not knowing to be a lesser emotional burden as well as a lesser risk of being denied healthcare should their insurance carrier learn the test result. In either case the patient\'s choice should be respected.

Inquiring into the family history can also identify relatives who may be at risk of having inherited the genetic basis for FTDP-17 and who thus may be presymptomatic.

Clinical genetic testing of affected and presymptomatic individuals is commercially available for some mutations. However, there tends to be little interest among at-risk family members to undergo clinical genetic testing \[[@B29]\].

Antenatal diagnosis
===================

Once a genetic basis for a subtype of FTDP-17 is discovered and testing for that gene becomes commercially available, it becomes possible, in principle, to identify that gene antenatally by sampling amniotic fluid or by preimplantation genetic diagnosis. Genetic counseling should accompany antenatal genetic diagnosis.

Management including treatment
==============================

Currently, a curative treatment for FTDP-17 does not exist, and most patients respond poorly, if at all, to levodopa. Palliative and symptomatic interventions are the mainstay of treatment. Physical therapy can be helpful to preserve some measure of mobility and independence in activities of daily living and to reduce the risk of falling. Stool softening agents are recommended for constipation. Speech therapy, swallowing assessment, and switching to a softer diet may be helpful for dysphagia. Anticholinergics may be helpful for sialorrhea or urinary frequency but carry the risk of aggravating mental confusion. Clozapine or quetiapine may be helpful for psychosis not explained by systemic infection or responsive to medication withdrawal. Antidepressant medications may be indicated for concurrent depression. Bed-bound patients will require frequent repositioning or air flow mattresses. Patients should be encouraged to discuss their treatment preferences with their families and their physicians and to indicate their choices by advance directives.

Prognosis
=========

The prognosis varies considerably. Most patients with FTDP-17 will experience several months to one or two years of moderate impairment followed by an unremitting downward course of physical and cognitive decline. The rate of progression varies greatly among individual patients and genetic kindreds, ranging from life expectancies of several months to several years, and, in exceptional cases, as long as two decades. In addition to the clinical features described above, in the late stages of illness these patients often develop secondary medical problems associated with immobility including falling injuries and respiratory and urinary tract infections.

Unresolved questions
====================

It is hoped that further research will identify the genetic modifiers and environmental factors that influence the variable penetrance and clinical expression of FTDP-17. The development of transgenic mice may provide an opportunity to test novel therapeutic agents in the near future.
